替吉奥联合奥沙利铂治疗晚期大肠癌的临床分析

Clinical Analysis of Tigeol Combined with Oxaliplatin in the Treatment of Advanced Colorectal Cancer

目的探讨大肠癌晚期患者通过替吉奥、奥沙利铂联合治疗的效果。方法随机选取该院2015年10月—2018年3月收治的大肠癌晚期患者102例,依据治疗方式差异分作两组,51例予以卡培他滨联合奥沙利铂治疗者作对照组,51例通过替吉奥联合奥沙利铂者作治疗组,回顾性对比分析两组疗效。结果治疗组临床受益率是96.08%,较对照组的82.35%高,差异有统计学意义(χ~2=4.679,P=0.030);治疗组不良反应发生率较对照组低,差异有统计学意义(χ~2=4.679、7.412、7.141、8.279、14.553、9.375、7.933、9.714,P=0.030、0.006、0.007、0.004、0.000、0.002、0.005、0.002)。结论通过替吉奥、奥沙利铂联合对大肠癌晚期患者展开治疗不仅临床受益率高,且不良反应少,值得选用。

Objective To investigate the effect of combined treatment with tiggio and oxaliplatin in patients with advanced colorectal cancer. Methods A total of 102 patients with advanced colorectal cancer admitted to the hospital from October 2015 to March 2018 were randomly selected. According to the difference of treatment methods, 51 patients were treated with capecitabine and oxaliplatin as control group. 51 patients were treated with tiogin combined with oxaliplatin. The efficacy of the two groups was retrospectively compared. Results The clinical benefit rate of the treatment group was 96.08%, which was higher than that of the control group,the difference was statistically significant（x^2=4.679, P=0.030）. The incidence of adverse reactions in the treatment group was lower than that of the control group,the different was statistically significant （X^2=4.679, 7.412, 7.141, 8.279, 14.553, 9.375, 7.933, 9.714, P=0.030, 0.006, 0.007, 0.004, 0.000, 0.002, 0.005, 0.002）. Conclusion The combination of tiggio and oxaliplatin in the treatment of patients with advanced colorectal cancer not only has a high clinical benefit rate, but also has few adverse reactions and is worthy of selection.